Immunocore to present four posters at AACR Annual Meeting 2023
14 mars 2023 16h30 HE
|
Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
Immunocore Reports 2022 Financial Results and Provides Business Update
01 mars 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in...
Immunocore to present at upcoming investor conferences
28 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
23 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore...
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
22 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial...
Immunocore to present at upcoming investor conferences
01 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
09 janv. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024;...
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq:...
Immunocore is awarded the Prix Galien France award for KIMMTRAK
15 déc. 2022 06h00 HE
|
Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
08 déc. 2022 06h30 HE
|
Immunocore Holdings Limited
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4...